Compound catalog
Cagrilintide (10mg)
How It Works Mechanism: It activates both amylin and calcitonin receptors in the hypothalamus, curbing cravings and reducing food intake. Amylin vs. GLP-1: Unlike GLP-1 agonists (such as semaglutide) which affect incretin pathways, cagrilintide operates via a completely separate, additive satiety signal. Clinical Research and EfficacyMonotherapy: In phase 3 clinical trials, cagrilintide alone has demonstrated meaningful body-weight reductions. Combination Therapy: Its most widely researched application is in combination with semaglutide and Retatrutide. Trial data for this dual-mechanism pairing suggests substantial weight reductions.
Documentation and release
Documentation pending
No product-specific analytical documentation is attached to this compound record yet.
Reviews
Researcher reviews
No reviews yet — be the first to leave one.